NZ Herald
  • Home
  • Latest news
  • Herald NOW
  • Video
  • New Zealand
  • Sport
  • World
  • Business
  • Entertainment
  • Podcasts
  • Quizzes
  • Opinion
  • Lifestyle
  • Travel
  • Viva
  • Weather

Subscriptions

  • Herald Premium
  • Viva Premium
  • The Listener
  • BusinessDesk

Sections

  • Latest news
  • New Zealand
    • All New Zealand
    • Crime
    • Politics
    • Education
    • Open Justice
    • Scam Update
  • Herald NOW
  • On The Up
  • World
    • All World
    • Australia
    • Asia
    • UK
    • United States
    • Middle East
    • Europe
    • Pacific
  • Business
    • All Business
    • MarketsSharesCurrencyCommoditiesStock TakesCrypto
    • Markets with Madison
    • Media Insider
    • Business analysis
    • Personal financeKiwiSaverInterest ratesTaxInvestment
    • EconomyInflationGDPOfficial cash rateEmployment
    • Small business
    • Business reportsMood of the BoardroomProject AucklandSustainable business and financeCapital markets reportAgribusiness reportInfrastructure reportDynamic business
    • Deloitte Top 200 Awards
    • CompaniesAged CareAgribusinessAirlinesBanking and financeConstructionEnergyFreight and logisticsHealthcareManufacturingMedia and MarketingRetailTelecommunicationsTourism
  • Opinion
    • All Opinion
    • Analysis
    • Editorials
    • Business analysis
    • Premium opinion
    • Letters to the editor
  • Politics
  • Sport
    • All Sport
    • OlympicsParalympics
    • RugbySuper RugbyNPCAll BlacksBlack FernsRugby sevensSchool rugby
    • CricketBlack CapsWhite Ferns
    • Racing
    • NetballSilver Ferns
    • LeagueWarriorsNRL
    • FootballWellington PhoenixAuckland FCAll WhitesFootball FernsEnglish Premier League
    • GolfNZ Open
    • MotorsportFormula 1
    • Boxing
    • UFC
    • BasketballNBABreakersTall BlacksTall Ferns
    • Tennis
    • Cycling
    • Athletics
    • SailingAmerica's CupSailGP
    • Rowing
  • Lifestyle
    • All Lifestyle
    • Viva - Food, fashion & beauty
    • Society Insider
    • Royals
    • Sex & relationships
    • Food & drinkRecipesRecipe collectionsRestaurant reviewsRestaurant bookings
    • Health & wellbeing
    • Fashion & beauty
    • Pets & animals
    • The Selection - Shop the trendsShop fashionShop beautyShop entertainmentShop giftsShop home & living
    • Milford's Investing Place
  • Entertainment
    • All Entertainment
    • TV
    • MoviesMovie reviews
    • MusicMusic reviews
    • BooksBook reviews
    • Culture
    • ReviewsBook reviewsMovie reviewsMusic reviewsRestaurant reviews
  • Travel
    • All Travel
    • News
    • New ZealandNorthlandAucklandWellingtonCanterburyOtago / QueenstownNelson-TasmanBest NZ beaches
    • International travelAustraliaPacific IslandsEuropeUKUSAAfricaAsia
    • Rail holidays
    • Cruise holidays
    • Ski holidays
    • Luxury travel
    • Adventure travel
  • Kāhu Māori news
  • Environment
    • All Environment
    • Our Green Future
  • Talanoa Pacific news
  • Property
    • All Property
    • Property Insider
    • Interest rates tracker
    • Residential property listings
    • Commercial property listings
  • Health
  • Technology
    • All Technology
    • AI
    • Social media
  • Rural
    • All Rural
    • Dairy farming
    • Sheep & beef farming
    • Horticulture
    • Animal health
    • Rural business
    • Rural life
    • Rural technology
    • Opinion
    • Audio & podcasts
  • Weather forecasts
    • All Weather forecasts
    • Kaitaia
    • Whangārei
    • Dargaville
    • Auckland
    • Thames
    • Tauranga
    • Hamilton
    • Whakatāne
    • Rotorua
    • Tokoroa
    • Te Kuiti
    • Taumaranui
    • Taupō
    • Gisborne
    • New Plymouth
    • Napier
    • Hastings
    • Dannevirke
    • Whanganui
    • Palmerston North
    • Levin
    • Paraparaumu
    • Masterton
    • Wellington
    • Motueka
    • Nelson
    • Blenheim
    • Westport
    • Reefton
    • Kaikōura
    • Greymouth
    • Hokitika
    • Christchurch
    • Ashburton
    • Timaru
    • Wānaka
    • Oamaru
    • Queenstown
    • Dunedin
    • Gore
    • Invercargill
  • Meet the journalists
  • Promotions & competitions
  • OneRoof property listings
  • Driven car news

Puzzles & Quizzes

  • Puzzles
    • All Puzzles
    • Sudoku
    • Code Cracker
    • Crosswords
    • Cryptic crossword
    • Wordsearch
  • Quizzes
    • All Quizzes
    • Morning quiz
    • Afternoon quiz
    • Sports quiz

Regions

  • Northland
    • All Northland
    • Far North
    • Kaitaia
    • Kerikeri
    • Kaikohe
    • Bay of Islands
    • Whangarei
    • Dargaville
    • Kaipara
    • Mangawhai
  • Auckland
  • Waikato
    • All Waikato
    • Hamilton
    • Coromandel & Hauraki
    • Matamata & Piako
    • Cambridge
    • Te Awamutu
    • Tokoroa & South Waikato
    • Taupō & Tūrangi
  • Bay of Plenty
    • All Bay of Plenty
    • Katikati
    • Tauranga
    • Mount Maunganui
    • Pāpāmoa
    • Te Puke
    • Whakatāne
  • Rotorua
  • Hawke's Bay
    • All Hawke's Bay
    • Napier
    • Hastings
    • Havelock North
    • Central Hawke's Bay
    • Wairoa
  • Taranaki
    • All Taranaki
    • Stratford
    • New Plymouth
    • Hāwera
  • Manawatū - Whanganui
    • All Manawatū - Whanganui
    • Whanganui
    • Palmerston North
    • Manawatū
    • Tararua
    • Horowhenua
  • Wellington
    • All Wellington
    • Kapiti
    • Wairarapa
    • Upper Hutt
    • Lower Hutt
  • Nelson & Tasman
    • All Nelson & Tasman
    • Motueka
    • Nelson
    • Tasman
  • Marlborough
  • West Coast
  • Canterbury
    • All Canterbury
    • Kaikōura
    • Christchurch
    • Ashburton
    • Timaru
  • Otago
    • All Otago
    • Oamaru
    • Dunedin
    • Balclutha
    • Alexandra
    • Queenstown
    • Wanaka
  • Southland
    • All Southland
    • Invercargill
    • Gore
    • Stewart Island
  • Gisborne

Media

  • Video
    • All Video
    • NZ news video
    • Herald NOW
    • Business news video
    • Politics news video
    • Sport video
    • World news video
    • Lifestyle video
    • Entertainment video
    • Travel video
    • Markets with Madison
    • Kea Kids news
  • Podcasts
    • All Podcasts
    • The Front Page
    • On the Tiles
    • Ask me Anything
    • The Little Things
  • Cartoons
  • Photo galleries
  • Today's Paper - E-editions
  • Photo sales
  • Classifieds

NZME Network

  • Advertise with NZME
  • OneRoof
  • Driven Car Guide
  • BusinessDesk
  • Newstalk ZB
  • Sunlive
  • ZM
  • The Hits
  • Coast
  • Radio Hauraki
  • The Alternative Commentary Collective
  • Gold
  • Flava
  • iHeart Radio
  • Hokonui
  • Radio Wanaka
  • iHeartCountry New Zealand
  • Restaurant Hub
  • NZME Events

SubscribeSign In
Advertisement
Advertise with NZME.
Home / World

The Conversation: Covid 19 coronavirus - Pfizer trialling pill to beat virus

Other
31 May, 2021 11:25 PM5 mins to read

Subscribe to listen

Access to Herald Premium articles require a Premium subscription. Subscribe now to listen.
Already a subscriber?  Sign in here

Listening to articles is free for open-access content—explore other articles or learn more about text-to-speech.
‌
Save

    Share this article

Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time -0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions settings, opens captions settings dialog
    • captions off, selected

      This is a modal window.

      Playback Denied: Unavailable

      Error Code: VIDEO_CLOUD_ERR_VIDEO_NOT_PLAYABLE
      Technical details :
      Video is not currently available for playback.
      Session ID: 2025-07-14:65e8f349cd0f2a24a9aa5e01 Player Element ID: vjs_video_6256821681001

      Beginning of dialog window. Escape will cancel and close the window.

      Text
      Text Background
      Caption Area Background
      Font Size
      Text Edge Style
      Font Family

      End of dialog window.

      This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

      Jury finds Erin Patterson guilty of murder

      UP NEXT:

      Autoplay in
      2
      Disable Autoplay
      Cancel Video
      Executive director of the WHO Health Emergencies Programme Dr. Michael Ryan called for the separation of politics from the science in searching for COVID's origins. Video / AP

      While the focus has been largely on vaccines, you might have also heard Pfizer is trialling a pill to treat Covid-19.

      It almost sounds too good to be true. Indeed, the results are very preliminary — but it's a promising approach.

      Where most antiviral agents we've tried to treat Covid-19 target the inflammatory and immune response resulting from infection, Pfizer's pill directly targets SARS-CoV-2 — the virus itself.

      Read More

      • Covid 19 coronavirus: Victoria lockdown may be extended over 'concerning' aged care case - NZ Herald
      • Covid 19 coronavirus: 13 Kiwis referred to 'people-finding services'; no new community Covid cases
      • Covid 19 coronavirus: Around the world - situation update - NZ Herald
      • Covid 19 coronavirus: Seven new cases - all at the border - NZ Herald

      Mounting our defence against the virus

      Advertisement
      Advertise with NZME.
      Advertisement
      Advertise with NZME.

      Much of the illness associated with Covid-19 is due to the intense inflammatory and immune response that can occur with an infection. The most successful treatments so far have targeted this overzealous immune response.

      Taken early in the disease, the inhaled corticosteroid budesonide has been shown to reduce the development of more severe disease.

      In people hospitalised with Covid-19 requiring oxygen, the oral corticosteroid dexamethasone reduces the likelihood of death.

      In the most severe cases — Covid patients admitted to ICU — the anti-inflammatory tocilizumab administered intravenously gives a person a better chance of survival.

      Advertisement
      Advertise with NZME.

      But these treatments don't target SARS-CoV-2 itself; just the consequences of infection. Directly targeting the virus has proven to be more difficult.

      Targeting SARS-CoV-2

      A virus like SARS-CoV-2 must enter a host cell to reproduce. It does this using its spike protein (a protein on the virus' surface) to attach to the cell, and then it uses the cell's own proteins to gain entry.

      Once inside the cell, SARS-CoV-2 removes its outer coat and releases its viral RNA (ribonucleic acid, a type of genetic material). This acts as a template, allowing the virus to replicate, and then infect other cells. At any point of this life cycle the virus could be vulnerable to an intervention.

      Discover more

      Opinion

      Teuila Fuatai: No quick fix to Sāmoa's political crisis

      01 Jun 05:00 PM
      World

      Has the outbreak spread? Victoria case confirmed in NSW

      01 Jun 06:55 PM
      World

      'Two-track pandemic': 75% of all Covid jabs given in just 10 countries

      01 Jun 08:52 PM
      The Conversation
      The Conversation

      SARS-CoV-2 carries an enzyme, 3C-like protease (3CLpro), which plays a crucial role in the replication process. This protease is almost identical to the protease used by the SARS-CoV-1 (SARS) virus, and similar to the protease used by the Middle Eastern Respiratory Virus (MERS).

      So a drug that could effectively target 3CLpro and prevent virus replication could be beneficial against multiple known coronaviruses, and possibly any that emerge in the future.

      Protease inhibitors have been successfully used to treat other viral infections, especially chronic infections such as HIV and hepatitis C.

      They were put forward early in the pandemic as a possible treatment for Covid-19. But the HIV drug lopinavir-ritonavir was shown in two clinical trials to be ineffective, with drug levels probably too low to work against SARS-CoV-2. While a higher dose might be effective, it would also likely produce more side effects.

      Covid

      Scientists also proposed a repurposed antiviral drug, remdesevir, originally developed to treat Ebola. Remdesivir delays the ability of the virus to replicate its RNA.

      Initial case reports appeared promising and saw the US Food and Drugs Administration approve the drug for emergency use. But the results of randomised controlled trials in hospitalised patients with severe Covid-19 were disappointing.

      Advertisement
      Advertise with NZME.

      Although there was a reduction in duration of illness for patients who survived, it didn't significantly reduce a person's chance of dying.

      Of course, neither of these agents were designed specifically to target SARS-CoV-2. But in 2020, Pfizer/BioNtech identified a small molecule — PF-00835231 — that blocks the SARS-CoV-2 3CLpro protease. It was originally designed against SARS-CoV-1, but the enzyme in the two viruses is almost identical.

      PF-00835231, both alone and in conjunction with remdesevir, appears to reduce the replication of a range of coronaviruses including SARS-CoV-2 in cells in the lab. It also reduced viral replication in a number of animal models, with no adverse safety signals. But it's important to note this research hasn't yet been peer reviewed.

      What now?

      Pfizer/BioNtech are taking two drugs to clinical trials for Covid-19: PF-07304814, an intravenous injection for use in patients hospitalised with severe Covid-19 and PF-07321332, an oral agent, or pill, that could potentially be used earlier in the disease. Both are formulations of a 3CLpro inhibitor.

      These phase 1 trials, which began in March, represent the earliest stage of drug development. These trials select healthy volunteers and use different doses of the drugs to establish their safety. They also look at whether the drugs elicit sufficient responses in the body to indicate they could be effective against SARS-CoV-2.

      Advertisement
      Advertise with NZME.

      The next step would be phase 2 or 3 trials to see if they improve outcomes in Covid-19. Usually this process takes years, but as the pandemic continues to rage globally, Pfizer says it will do this in a matter of months, if phase 1 trials are successful.

      The application of antiviral agents in acute Covid-19 has been difficult and unrewarding. Though results are at this stage preliminary, these agents by Pfizer/BioNtech are promising. They could be used early in disease, especially in people poorly protected by vaccination or in those who haven't been vaccinated.

      They could also be used as a means of prevention, to contain outbreaks in exposed people. They should be effective against all the SARS-CoV-2 variants of concern, as well as against other known and possibly emergent coronaviruses.

      The Pfizer CEO's recent suggestion the pill could be available by the end of the year is probably a long shot. But the pandemic has shown us what's possible in the realm of swift scientific advances, and we'll watch this space with interest.

      • Peter Wark, Conjoint Professor, School of Medicine and Public Health, University of Newcastle

      • This article is republished from The Conversation under a Creative Commons license. Read the original article.

      Advertisement
      Advertise with NZME.
      Save

        Share this article

      Latest from World

      World

      Gisele Pelicot to receive Legion of Honour

      14 Jul 12:29 AM
      World

      Two dead, state trooper and others injured in Kentucky shootings

      14 Jul 12:03 AM
      Premium
      Analysis

      American allies want to redraw the world’s trade map, minus the US

      13 Jul 11:04 PM

      From early mornings to easy living

      sponsored
      Advertisement
      Advertise with NZME.
      Recommended for you
      Teen's 900km ride for Māori wards ends with cheers at Parliament
      Rotorua Daily Post

      Teen's 900km ride for Māori wards ends with cheers at Parliament

      14 Jul 12:34 AM
      Gisele Pelicot to receive Legion of Honour
      World

      Gisele Pelicot to receive Legion of Honour

      14 Jul 12:29 AM
      Workplace incident at Remuera home leaves one critically injured
      Auckland

      Workplace incident at Remuera home leaves one critically injured

      14 Jul 12:17 AM
      The bed which profiles how you sleep
      Sponsored Stories

      The bed which profiles how you sleep

      14 Jul 12:17 AM
      Two dead, state trooper and others injured in Kentucky shootings
      World

      Two dead, state trooper and others injured in Kentucky shootings

      14 Jul 12:03 AM

      Latest from World

      Gisele Pelicot to receive Legion of Honour

      Gisele Pelicot to receive Legion of Honour

      14 Jul 12:29 AM

      Rape survivor waived anonymity in trial against her former husband and other defendants.

      Two dead, state trooper and others injured in Kentucky shootings

      Two dead, state trooper and others injured in Kentucky shootings

      14 Jul 12:03 AM
      Premium
      American allies want to redraw the world’s trade map, minus the US

      American allies want to redraw the world’s trade map, minus the US

      13 Jul 11:04 PM
      'Alligator Alcatraz' expected to cost $750m to operate for a year

      'Alligator Alcatraz' expected to cost $750m to operate for a year

      13 Jul 10:13 PM
      Solar bat monitors uncover secrets of Auckland’s night sky
      sponsored

      Solar bat monitors uncover secrets of Auckland’s night sky

      NZ Herald
      • About NZ Herald
      • Meet the journalists
      • Newsletters
      • Classifieds
      • Help & support
      • Contact us
      • House rules
      • Privacy Policy
      • Terms of use
      • Competition terms & conditions
      • Our use of AI
      Subscriber Services
      • NZ Herald e-editions
      • Daily puzzles & quizzes
      • Manage your digital subscription
      • Manage your print subscription
      • Subscribe to the NZ Herald newspaper
      • Subscribe to Herald Premium
      • Gift a subscription
      • Subscriber FAQs
      • Subscription terms & conditions
      • Promotions and subscriber benefits
      NZME Network
      • The New Zealand Herald
      • The Northland Age
      • The Northern Advocate
      • Waikato Herald
      • Bay of Plenty Times
      • Rotorua Daily Post
      • Hawke's Bay Today
      • Whanganui Chronicle
      • Viva
      • NZ Listener
      • Newstalk ZB
      • BusinessDesk
      • OneRoof
      • Driven Car Guide
      • iHeart Radio
      • Restaurant Hub
      NZME
      • About NZME
      • NZME careers
      • Advertise with NZME
      • Digital self-service advertising
      • Book your classified ad
      • Photo sales
      • NZME Events
      • © Copyright 2025 NZME Publishing Limited
      All Access. All in one subscription. From $2 per week
      Subscribe now

      All Access Weekly

      From $2 per week
      Pay just
      $15.75
      $2
      per week ongoing
      Subscribe now
      BEST VALUE

      All Access Annual

      Pay just
      $449
      $49
      per year ongoing
      Subscribe now
      Learn more
      30
      TOP
      search by queryly Advanced Search